儿童狼疮性肾炎分型及治疗策略

doi:10.12372/jcp.2023.23e0916

Abstract

Abstract:

Lupus nephritis (LN) is the most common glomerular disease in children, with a more severe onset and progression compared to adults. The prognosis of LN in children is worse than other glomerular diseases and has lifelong effects, although the etiology remains unclear. This article provides an overview of the current diagnosis and treatment status of LN in children, along with a brief description of the treatment for each type of LN based on the latest international guidelines. LN was diagnosed according to the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Renal biopsy pathology is an important diagnostic method at present. Treatment for proliferative and non-proliferative LN includes initial therapy and maintenance therapy, following recommendations from adult guidelines. Rational and proactive treatment is crucial for inducing disease remission, preventing relapse, and improving prognosis.

Key words: systemic lupus erythematosus, lupus nephritis, treatment, child

GAO Chunlin. Renal pathologic classification and treatment strategy in children with lupus nephritis[J].Journal of Clinical Pediatrics, 2023, 41(12): 887-894.

Figures/Tables 1

References 42

[1]	Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2010, 6(9): 538-546. doi: 10.1038/nrrheum.2010.121 pmid: 20683438
[2]	Feldman CH, Broder A, Guan H, et al. Sex differences in health care utilization, end-stage renal disease, and mortality among medicaid beneficiaries with incident lupus nephritis[J]. Arthritis Rheumatol, 2018, 70(3): 417-426. doi: 10.1002/art.v70.3
[3]	Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children[J]. Acta Paediatr Jpn, 1997, 39: 242-244. doi: 10.1111/ped.1997.39.issue-2
[4]	Tsioni V, Andreoli L, Meini A, et al. The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy[J]. Clin Exp Rheumatol, 2015, 33(5): 681-687. pmid: 26089119
[5]	Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups[J]. Lupus, 2016, 25(14): 1542-1550. pmid: 27147622
[6]	Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups[J]. Lupus, 2020, 29(5): 474-481. doi: 10.1177/0961203320909156 pmid: 32233733
[7]	Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population[J]. Arthritis Rheum, 2012, 64: 2669-2676. doi: 10.1002/art.v64.8
[8]	Massias JS, Smith EM, Al-Abadi E, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK[J]. Lupus, 2021, 30(4): 597-607. doi: 10.1177/0961203320984251 pmid: 33413005
[9]	Sassi RH, Hendler JV, Piccoli GF, et al. Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus[J]. Clin Rheumatol, 2017, 36(1): 89-95. doi: 10.1007/s10067-016-3478-4 pmid: 27858177
[10]	Wang SF, Chen YH, Chen DQ, et al. Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis[J]. Lupus, 2018, 27(2): 303-311. doi: 10.1177/0961203317720526 pmid: 28720048
[11]	Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis[J]. Pediatr Nephrol, 2021, 36: 1377-1385. doi: 10.1007/s00467-020-04686-1
[12]	Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial[J]. Arthritis Rheum, 2004, 50(12): 3934-3940. doi: 10.1002/art.v50:12
[13]	Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis[J]. Nat Rev Dis Primers, 2020, 6(1): 7. doi: 10.1038/s41572-019-0141-9
[14]	Lu R, Robertson JM, Bruner BF, et al. Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort[J]. Autoimmune Dis, 2012: 819634
[15]	Santacruz JC, Mantilla MJ, Rueda I, et al. A practical perspective of the hematologic manifestations of systemic lupus erythematosus[J]. Cureus, 2022, 14(3): e22938.
[16]	Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus[J]. Lupus Sci Med, 2015, 2(1): e000078. doi: 10.1136/lupus-2014-000078
[17]	Kocheril AP, Vettiyil GI, George AS, et al. Pediatric systemic lupus erythematosus with lupus anticoagulant hypoprothrombinemia syndrome-a case series with review of literature[J]. Lupus, 2021, 30(4): 641-648. doi: 10.1177/0961203321988934 pmid: 33509039
[18]	Suyama Y, Okada M, Rokutanda R, et al. Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: a retrospective cohort study[J]. Mod Rheumatol, 2016, 26(4): 557-561. doi: 10.3109/14397595.2015.1112467 pmid: 26587755
[19]	Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. doi: 10.1136/annrheumdis-2020-216924 pmid: 32220834
[20]	Kidney Disease: Improving Global Outcomes KDIGO Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular Diseases[J]. Kidney Int, 2021, 100(4S): S1-S276. doi: 10.1016/j.kint.2021.05.021 pmid: 34556256
[21]	Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819 pmid: 31383717
[22]	中华医学会儿科分会肾脏学组. 儿童狼疮性肾炎诊治循证指南(2016)[J]. 中华儿科杂志, 2018, 56(2): 88-94.
[23]	Wakiguchi H, Takei S, Kubota T, et al. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels[J]. Clin Rheumatol, 2017, 36(2): 433-437. doi: 10.1007/s10067-016-3491-7 pmid: 27900491
[24]	Narváez J, Ricse M, Gomà M, et al. The value of repeat biopsy in lupus nephritis flares[J]. Medicine (Baltimore), 2017, 96(24): e7099. doi: 10.1097/MD.0000000000007099
[25]	Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kidney Int, 2004, 65(2): 521-530. doi: 10.1111/j.1523-1755.2004.00443.x pmid: 14717922
[26]	Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices[J]. Kidney Int, 2018, 93(4): 789-796. doi: S0085-2538(17)30859-1 pmid: 29459092
[27]	Hu W, Chen Y, Wang S, et al. Clinical-morphological features and outcomes of lupus podocytopathy[J]. Clin J Am Soc Nephrol, 2016, 11(4): 585-592. doi: 10.2215/CJN.06720615
[28]	Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis[J]. Nat Rev Nephrol, 2011, 7(12): 718-729. doi: 10.1038/nrneph.2011.150
[29]	Yusuf IH, Charbel Issa P, Ahn SJ. Hydroxychloroquine-induced retinal toxicity[J]. Front Pharmacol, 2023, 14: 1196783. doi: 10.3389/fphar.2023.1196783
[30]	Anders HJ, Loutan J, Bruchfeld A, et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021[J]. Nephrol Dial Transplant, 2023, 38(3): 551-561. doi: 10.1093/ndt/gfab351
[31]	Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide[J]. Ann Rheum Dis, 2010, 69(1): 61-64. doi: 10.1136/ard.2008.102533 pmid: 19155235
[32]	Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis[J]. J Am Soc Nephrol, 2009, 20: 1103-1112. doi: 10.1681/ASN.2008101028 pmid: 19369404
[33]	Yang TH, Wu TH, Chang YL, et al. Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus[J]. Clin Nephrol, 2018, 89: 277-285. doi: 10.5414/CN109325
[34]	Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353: 2219-2228. doi: 10.1056/NEJMoa043731
[35]	Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine[J]. Lupus, 2005, 14: 265-272. doi: 10.1191/0961203305lu2081oa pmid: 15864912
[36]	Zhang M, Qi C, Zha Y, et al. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial[J]. Clin Rheumatol, 2019, 38: 859-867. doi: 10.1007/s10067-018-4348-z pmid: 30426311
[37]	Furie R, Rovin BH, Houssiau F, et al. Safety and efficacy of belimumab in patients with lupus nephritis open-label extension of BLISS-LN study[J]. Clin J Am Soc Nephrol, 2022, 17: 1620-1630. doi: 10.2215/CJN.02520322
[38]	Austin HA, 3rd, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy[J]. J Am Soc Nephrol, 2009, 20: 901-911. doi: 10.1681/ASN.2008060665 pmid: 19297556
[39]	Wasik H, Chadha V, Galbiati S, et al. Dialysis outcomes for children with lupus nephritis compared to children with other forms of nephritis: a retrospective cohort study[J]. Am J Kidney Dis, 2022, 79(5): 626-634. doi: 10.1053/j.ajkd.2021.07.013
[40]	Mai K, Singer P, Fahmy AE, et al. Kidney transplant outcomes in children and adolescents with systemic lupus erythematosus[J]. Pediatr Transplant, 2022, 26(1): e14178. doi: 10.1111/petr.v26.1
[41]	Gipson DS, Ferris ME, Dooley MA, et al. Renal transplantation in children with lupus nephritis[J]. Am J Kidney Dis, 2003, 41(2): 455-463. pmid: 12552510
[42]	Rangoonwala S, Marks SD. Kidney transplantation outcomes for children and young people with lupus nephritis[J]. Pediatr Transplant, 2022, 26(1): e14193. doi: 10.1111/petr.v26.1

治疗	方案	LN Ⅰ、Ⅱ型	LN Ⅲ、Ⅳ（±Ⅴ）型	LN Ⅴ型
初始治疗	常用方案	①非肾病范围蛋白尿：肾外表现来决定免疫抑制剂 ②肾病范围蛋白尿：GC ③镜下血尿：不需要针对肾病治疗 ④足细胞病：GC	①GC+MPAA ②GC+CTX ③GC+贝利尤单抗+MPAA或低剂量CTX ④GC+MPAA+CNIs	①非肾病范围蛋白尿：肾外表现来决定免疫抑制剂 ②肾病范围蛋白尿：GC+MPAA或GC+CTX（<6个月）或GC+CNIs或GC+利妥昔单抗（RTX）或GC+AZA
初始治疗	替代方案		GC+AZA GC+来氟米特
维持治疗		MPAA/AZA/贝利尤单抗
基础治疗	羟氯喹

Renal pathologic classification and treatment strategy in children with lupus nephritis

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 42

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LUO Mingjing, YU Jiaming, WANG Xiaodong, ZHANG Xiaoling, YU Yue, ZHANG Yu, WEN Feiqiu, LIU Sixi. Clinical analysis of invasive fungal disease secondary to allogeneic hematopoietic stem cell transplantation in 424 children with thalassemia [J]. Journal of Clinical Pediatrics, 2025, 43(1): 21-28.
[2]	LIU Dongxia, JIN Rong, LIN Rongjun. Risk factors analysis of severe refractory Mycoplasma pneumoniae pneumonia complicated with bronchitis obliterans in children [J]. Journal of Clinical Pediatrics, 2025, 43(1): 29-34.
[3]	LUO Zhiqiang, CHEN Li, LU Xinguo, LIAO Jianxiang, LUO Xufeng. The treatment of the first case of presymptomatic spinal muscular atropy in the Chinese Mainland: a case report with 43 months follow-up [J]. Journal of Clinical Pediatrics, 2025, 43(1): 40-44.
[4]	ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55.
[5]	JIANG Weiqin, WANG Jing, CHENG Anna, CHEN Tingting, HUANG Yujuan. Predictors of recurrent febrile seizures during the same febrile illness in children with febrile seizures [J]. Journal of Clinical Pediatrics, 2025, 43(1): 8-13.
[6]	QIU Xiu, WEI Dongmei, LIN Shanshan, XIA Huimin, ZHOU Wenhao. Principles and practice of the Born in Guangzhou Cohort Study [J]. Journal of Clinical Pediatrics, 2024, 42(9): 747-752.
[7]	FAN Jianxia. The origins and development of the healthy life trajectory program: a cohort of community-family-mother-child multidimensional interventions for overweight and obesity in children [J]. Journal of Clinical Pediatrics, 2024, 42(9): 768-773.
[8]	JIANG Tao, LI Shuangjie, TANG Lian, OUYANG Wenxian. Immunobiological properties of peripheral blood MAIT cells in children with chronic hepatitis B [J]. Journal of Clinical Pediatrics, 2024, 42(9): 787-790.
[9]	ZHOU Jie, LIU Keqiang, WANG Jinling, WANG Ying. Megacystis-microcolon-intestinal hypoperistalsis syndrome caused by MYH11 elongating mutation : a case report and literatures review [J]. Journal of Clinical Pediatrics, 2024, 42(9): 798-804.
[10]	CHU Sijia, TANG Jihong. Research progress of central nervous system injury associated with pediatric acute lymphoblastic leukemia and its treatment [J]. Journal of Clinical Pediatrics, 2024, 42(9): 811-816.
[11]	DING Yaping, XIA Shanshan, ZHANG Chenmei. Interpretation of “2023 Children’s Renal Nutrition Working Group Clinical Practice Recommendations: Nutritional Management of Children with Acute Kidney Injury” [J]. Journal of Clinical Pediatrics, 2024, 42(8): 667-672.
[12]	LI Yirong, LI Huiping, GAO Jingyu, XIAO Yuhua, CHEN Xiaomin, LU Yanling, ZHAO Nana, FENG Xiaoqin. Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen [J]. Journal of Clinical Pediatrics, 2024, 42(8): 673-677.
[13]	HUANG Bo, DONG Yanying, SONG Linlan. Clinical characteristics of 348 children with infectious mononucleosis [J]. Journal of Clinical Pediatrics, 2024, 42(8): 678-683.
[14]	WANG Dan, SHAO Jingbo, LI Hong, ZHANG Na, ZHU Jiashi, FU Pan, WANG Zhen. Clinical analysis of 38 cases of hematological malignancies complicated with tumor lysis syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 684-690.
[15]	MA Yan, WEI Xingjiao, BAI Hua, ZHANG Yan, TIAN Xinmin, Aqsa Ahmad, LIANG Lijun. Analysis of etiological composition and clinical features of stage 5 chronic kidney disease in children in a tertiary hospital in western China [J]. Journal of Clinical Pediatrics, 2024, 42(8): 697-703.